Proteomics International receives $2.2m in R&D tax incentive
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Proteomics International Laboratories Ltd. has announced the receipt of a significant research and development tax incentive, which has bolstered its cash reserves. The company received a rebate for its R&D expenditures during the financial year, which supports its ongoing development of innovative diagnostic tests. Proteomics International is focused on advancing its diagnostic pipeline, including tests for various medical conditions using its Promarker® technology platform. This funding is part of the Australian Government's initiative to encourage beneficial research activities within the country.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- PromarkerEndo test for endometriosis receives $0.5m grant
- Collaboration expanded to advance Endometriosis blood test
- Proteomics granted certification for Diagnostics Laboratory
- Board and Management Transition
- PromarkerEso precisely detects early stage esophageal cancer
Later from Proteomics International Laboratories
- OxiDx test correlates with superior racehorse performance
- US Medicare sets reimbursement price for PromarkerD DKD test
- Response to ASX Price Query
- PromarkerD predicts risk of DKD in Aboriginal Australians
- US patent secured for PromarkerEso diagnostic test for EAC
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories